Amgen CEO Net Worth

Last Updated Mar 10, 2025
CEO NameRobert A. Bradway
NationalityUnited States
Net Worth Estimation$125 million

Robert A. Bradway's estimated net worth of around $125 million primarily derives from his long tenure as CEO and Chairman of Amgen, combined with substantial annual compensation, stock grants, and accumulated shareholdings in the biotechnology company. His executive roles and performance-based incentives at Amgen have significantly increased his personal wealth over time.

Robert A. Bradway, CEO of Amgen in the biotechnology sector, has an estimated net worth of $125,000,000, which is 56% higher than the category's maximum range of $80,000,000. His net worth exceeds the minimum CEO net worth in this field by 1150%.

Business Category: Biotechnology

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD


Robert A. Bradway Performance in Amgen

Robert A. Bradway, CEO of Amgen, demonstrates strong leadership through strategic decision-making focused on innovation and sustainable growth. His performance is marked by driving pipeline expansion, leveraging acquisitions, and enhancing shareholder value. Under Bradway's leadership, Amgen has solidified its position as a leading biopharmaceutical firm with increased revenues and robust R&D investments.


Latest News

Amgen's Recent Developments and CEO Robert Bradway's Leadership

Amgen announced a $2.38 per share dividend for Q4 2025 and a $650 million U.S. manufacturing expansion creating hundreds of new jobs under CEO Robert Bradway, who also revealed a $1 billion investment to expand manufacturing capacity. Bradway, who earned $21.4 million in 2022, leads Amgen in breakthrough biotech innovations and strategic growth initiatives.
Source: http://www.prnewswire.com/news-releases/amgen-announces-2025-fourth-quarter-dividend-302601323.html



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Amgen are subject to change from time to time.

Comments

No comment yet